AllDocs -> cancers

Telephone 13 11 20 for cancer information and support Lymphoma non-Hodgkin lymphoma and Hodgkin lymphoma Lymphoma non-Hodgkin lymphoma and Hodgkin lymphoma A GUIDE FOR PEOPLE WITH CANCER,THEIR FAMILIES AND FRIENDS A GUIDE FOR PEOPLE WITH CANCER,THEIR FAMILIES AND FRIENDS 13 11 20 13 11 20 IF YOU NEED TO TALK TO SOMEONE,CALL THE CANCER HELPLINE ON IF YOU NEED TO TALK TO SOMEONE,CALL THE CANCER HELPLINE ON Page 2 Leading the fight against cancer Lymphoma First published December 1997 This edition July 2004 Acknowledgments The Cancer Council thanks everyone who contributed to the development and revision of this booklet. Illustration on page 7 by Con Stamatis. Many Cancer Council services, including ...

Lymphoma Manifesto Lymphatic Cancer Alliance November 2005 Page 2 E very hour of every day one person in the UK is diagnosed with lymphatic cancer. Around 45,000 people in the UK are living with the disease and incidence is rising. Given the appropriate treatment at the appropriate time, many lymphoma patients can have their disease managed effectively or even be cured. There have been huge advances in treatment which have resulted in more patients surviving, and with a better quality of life. However much remains to be done. This manifesto identifies the changes that are required throughout the patient journey if all today’s lymphoma patients, as well as the growing numbers who will have the disease in the future, are to receive the best treatment. If these changes are to be delivered, then greater resources will need to be allocated ...

B.C. Cancer Agency Protocol Summary LYFLU Page 1 of 2 H:\Pharm-prov\Provincial DI Coordinator\UPDATE\UpdateImplementation\LYFLU_1Sep06.doc Printed on 8/29/2006 11:29:00 AM BCCA Protocol Summary for Treatment of Low Grade Lymphoma or Chronic Lymphocytic Leukemia with Fludarabine Protocol Code LYFLU Tumour Group Lymphoma Contact Physician Dr. Joseph Connors ELIGIBILITY : Symptomatic or threatening advanced stage indolent lymphoma (small lymphocytic lymphoma , lymphoplasmacytic lymphoma [formerly Waldenstrom's macroglobulinemia], marginal zone lymphoma or follicular lymphoma ) or chronic lymphocytic leukemia TESTS : Baseline: CBC & diff, serum creatinine, HBsAg, HBcoreAb Before each treatment: CBC & diff, serum creatinine PREMEDICATIONS : None TREATMENT : Drug Dose BCCA Administration ...

BCCA Protocol Summary for Treatment of Cutaneous T-cell Lymphoma (Sézary syndrome) with Extracorporeal Photopheresis Protocol Code ULYMFECP Tumour Group Lymphoma Contact Physician Dr. Nicholas Voss ELIGIBILITY : Special: Only patients with advanced, progressive, refractory cutaneous T-cell lymphoma (erythroderma or stages T2/3 with circulating Sézary cells) who have failed at least two prior systemic chemotherapy agents, not including retinoids, and have failed or are unable to tolerate Bexarotene should be considered for ECP. This means that they have either failed to respond to or have relapsed after these treatments. Histology: mycosis fungoides or Sézary syndrome Adequate immune system with near normal WBC (excluding Sézary cells) Normal/near normal CD8 count An “Undesignated Indications Request Form” must be approved. EXCLUSIONS ...

September Is Leukemia and Lymphoma Awareness Month What Is Leukemia? Leukemia is a cancer of the white blood cells, which help fight infection. It is caused by the uncontrolled growth of these cells. Leukemia starts in the bone marrow, which is the spongy part inside the bones where blood cells are made. The cancer cells spread to the blood that circulates in the arteries and veins. What Are the Key Statistics About Leukemia? • The American Cancer Society estimates that 35,070 people will be diagnosed with leukemia this year. • About 22,280 people are expected to die from leukemia in the year 2006. • Leukemia is commonly thought of as a childhood disease, yet it is diagnosed 10 times more often in adults. What Are the Types of Leukemia? • Based on the time it takes one to develop the disease, leukemia has two forms, ...

From the GRCA Health and Genetics Committee GOLDENS WITH LYMPHOMA AND OSTEOSARCOMA ARE NEEDED TO STUDY THE GENETIC BASIS OF LYMPHOMA AND OSTEOSARCOMA Most Golden Retriever fanciers know Goldens that have died of lymphoma (cancer of the lymph nodes, lymphosarcoma) and osteosarcoma (bone cancer). Since our Goldens are predisposed to these cancers, many of us have lost some of our own beloved Goldens to these diseases. The Canine Health Foundation has funded a study that may help determine the genetic basis of these cancers. We have hopes that this study and subsequent studies may some day lead to genetic tests to identify Goldens predisposed to developing lymphoma and bone cancer and may identify those lymphomas and bone cancers most likely to respond to treatment. If your Golden Retriever is newly diagnosed with lymphoma or osteosarcoma (has not yet started chemotherapy, including steroids), you ...

CCA Protocol Summary for Maintenance Rituximab for Indolent Lymphoma Protocol Code ULYRMTN Tumour Group Lymphoma Contact Physician Dr. Joseph Connors ELIGIBILITY : Indolent lymphoma : Follicular lymphoma , grade 1,2 or 3, Small Lymphocytic lymphoma , Lymphoplasmacytic lymphoma , Marginal zone lymphoma or lymphoma not otherwise classifiable, grade 1 after completion of a course of chemotherapy Stage: Advanced stage or relapse Response status: At least a partial response must have occurred in response to the preceding chemotherapy “Undesignated Indication Request” form must be completed and approved before treatment TESTS : Baseline (required before first treatment): CBC and diff, platelets, bilirubin Baseline (required, but results do not have to be available to proceed with first treatment): hepatitis Bs Ag, hepatitis ...

BCCA Protocol Summary for Lymphoma Palliative Chemotherapy Protocol Code LYPALL Tumour Group Lymphoma Contact Physician Dr. Joseph Connors ELIGIBILITY/TESTS : The following chemotherapeutic agents are occasionally useful as single agents in the palliative or symptomatic management of lymphoproliferative disease. Their use always requires knowledge of the diagnosis, other co-morbid illnesses, prior treatment and toxicity and current goals of treatment. In general these uses of chemotherapy should be based on prior experience in similar situations. Clinicians without such experience should discuss these uses with a chemotherapist from the Lymphoma Tumour Group. Because the doses and schedules of the chemotherapy agents listed below must be individualized a usual dose and schedule and a reasonable range is cited. Dose reductions for toxicity must be individualized. ...

55 International Pediatrics/Vol. 18/No. 1/2003 Burkitt’s Lymphoma Clinical Article The Endoscopic and Computed Tomographic Appearance of Burkitt’s Lymphoma of the Stomach with Follow-up Studies Ali Mirza Onder, MD; Jesse Reeves-Garica, MD Abstract This is a report of a previously healthy 17-year-old male who was initially presented with abdominal pain, vomiting, dyspepsia, gener- alized malaise, and weight loss for 3 months duration. As per history on admission, he did not benefit from two courses of Helicobacter pylori eradication treatment with antibiotics and proton-pump inhibi- tors. His initial work-up in another facility included an upper gas- trointestinal (GI) series which was negative. During the upper GI endoscopy, a large yellow-white ulcer crater was detected covering the lesser curvature of the stomach with a large blue hard mass central to the crater. ...

2007 Pan Pacific Lymphoma Conference PROGRAM FACULTY Lynne V. Abruzzo, MD, PhD Associate Professor Department of Hematopathology The University of Texas M. D. Anderson Cancer Center Houston, Texas Patricia Aoun, MD, MPH Associate Professor Department of Pathology and Microbiology University of Nebraska Medical Center Omaha, Nebraska James O. Armitage, MD Professor Section of Hematology/Oncology Department of Internal Medicine University of Nebraska Medical Center Omaha, Nebraska Tracy T. Batchelor, MD Executive Director, Stephen E. and Catherine Pappas Center for Neuro-Oncology Massachusetts General Hospital Harvard Medical School Boston, Massachusetts Phillip J. Bierman, MD Associate Professor Section of Hematology/Oncology Department of Internal Medicine University of Nebraska Medical ...

Non-Hodgkins Lymphoma – C82-C85 Cancer Statistics Cancer affects all ages, however, is predominately a disease that affects the elderly; the rate of cancer in any age-group rises continuously in both males and females from about the age of 30. The statistics presented here fall into three groups: Incidence, Mortality and Survival. Incidence and Mortality are reported in three ways : 1) Number: this is simply the number of cases cancer in an area and will depend on the population of that area and on the age structure of its population as well as on the underlying rate of cancer. 2) Crude rate per 100,000 population: this is the number of cases of cancer in an area divided by the population of that area. This measure takes account of the size of that population, but not its age structure; it would tend to be higher in areas where the population is older. 3) Age standardised rate per 100,000 ...

Available online at http://www.biij.org/2006/3/e36 doi: 10.2349/biij.2.3.e36 biij Biomedical Imaging and Intervention Journal CASE REPORT Axillary lymphoma masquerading as inflammatory breast cancer KL Taubman 1 , MBBS, FRACP, MJ McKay 2,* , FRANZCR, PhD 1 Department of Nuclear Medicine, St Vincent’s Hospital, Melbourne, Australia 2 Divisions of Radiation Oncology and Research, Peter MacCallum Cancer Centre, Melbourne, Australia Received 26 April 2006; received in revised form 24 June 2006; accepted 11 July 2006 ABSTRACT Primary non-Hodgkins lymphoma (NHL) of the breast, and its extranodal spread to the breast resulting from systemic lymphoma , are recognised albeit uncommon conditions. However, lymphoma involving the axilla, presenting with the clinical appearance ...

Lymphoma matters Lymphoma Association wins prestigious award The Lymphoma Association is delighted to be one of ten winners of a top award, recognising and promoting excellence in community healthcare. At the awards ceremony, held at the National Gallery in London on 18 April, the Lymphoma Association was presented with their certificate and a cheque for £20,000. The IMPACT Award is an annual scheme funded by GlaxoSmithKline in association with the King’s Fund. The scheme is designed to recognise and reward excellence among small-to-medium sized voluntary organisations, whose work has made a significant impact on the health of their target communities. Issue 66 Summer 2006 Registered Charity No.1068395 We are very grateful for sponsorship of this newsletter from Schering Health Care Ltd ...

What’s New in Cutaneous Lymphoma Youn H. Kim Department of Dermatology Multidisciplinary Cutaneous Lymphoma Group Stanford University School of Medicine Page 2 Disclosure of Conflicts of Interest Youn H. Kim, M.D. What’s New in Cutaneous Lymphoma Co-investigator in clinical trials sponsored by BioCryst, Coley/Pfizer, Aton/Merck, Curagen, Gloucester, Genmab, Seagen; Honorarium/grants from Scimed, Merck, Ligand, Ovation Page 3 What’s New in Cutaneous Lymphoma • Classification • Diagnosis • Staging • Therapy Page 4 Multidisciplinary Cutaneous Lymphoma Clinic/Program Multidisciplinary Cutaneous Lymphoma Clinic/Program Youn Kim, Director, Youn Kim, Director, Dermatology Dermatology ...

) for each team member. 3. Area of Study ( check all that apply) ? Etiology ? Pathogenesis ? Clinical Trials ? Translational Research : ? Prevention ? Developmental Therapeutics ? Other: ? Genomics ? Proteomics ? Biomarkers ? Other: 4. Vertebrate Animals ? Yes ? No If yes, specify IACUC approval date 5. Human Subjects ? Yes ? No If yes, specify IRB approval date or exemption number 6. Biohazards ? Yes ? No If yes, specify Biohazard Committee approval date or exemption number 7. Proposed Length of Study: ? 1 Year ? 2 years ? 3 years Cover Sheet (2 of 4) – C0-Applicants ...

Activation of CD19 in Acute Myeloid Leukemia and T-Cell Lymphoma /Leukemia Is Frequently Correlated with Expression of Its Upstream Transcriptional Activator PAX5 Henry Dong, Patti Cohen and Po-Shing Lee. Genzyme Genetics/IMPATH, Inc., New York, NY Background : CD19 is one of the most specific B-cell anti- gens. Aberrant expression of CD19 has been described in a subset of acute myeloid leukemia (AML), especially AML with t(8;21), and has been detected in extremely unusual cases of T cell lymphoma (TCL). Whether it is associated with the expression of its upstream regulatory gene PAX5 is uncertain. Materials and Methods : AML and TCL with coexpression of CD19 were identified by flow cytometry. PAX5 expression was studied by immunohistochemistry (IHC) with the mono- clonal antibody clone 24 (BD Bioscience) and was corre- lated with expression of other pan-B cell antigens. Results : ...

C O N T I N U I N G E D U C A T I O N The Role of PET in Lymphoma * Yuliya S. Jhanwar 1 and David J. Straus 2 1 Nuclear Medicine Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York; and 2 Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York Malignant lymphomas are a heterogeneous group of diseases whose treatment and prognosis depend on accurate staging and evaluation of histologic features. The conventional imaging procedure is CT; however, nuclear medicine imaging has also had a prominent role. Single-photon imaging with 67 Ga-citrate has been widely used for lymphomas. PET with 18 F-FDG has gained a role in the staging and follow-up of lymphomas, largely replac- ing gallium as the ...

Cisco Systems, Inc. All contents are Copyright © 1992–2004 Cisco Systems, Inc. All rights reserved. Important Notices and Privacy Statement. Page 1 of 3 EXECUTIVE SUMMARY CUSTOMER NAME The Leukemia & Lymphoma Society INDUSTRY Healthcare BUSINESS CHALLENGE Raise additional funds Enhance patient and family support services Improve business communications and maintain monthly network operating costs NETWORK SOLUTION High-performance Cisco switches and routers Cisco VPN concentrators BUSINESS VALUE Enhanced communication facilitates patient and family support services and fund-raising event coordination Network infrastructure supports new technologies for enhancing business operations and reducing operating expenses ABSTRACT A Cisco foundation ...

Chemosensitising Non-Hodgkin Lymphoma Cells using Protein Synthesis Inhibitors? Professor Anne Willis, School of Pharmacy, University of Nottingham The Background Non-Hodgkin lymphomas (NHL) comprise at least thirty distinct subtypes of B and T cell malignancies although over 90% of NHL are of B cell origin (Fischer 2003). At present NHL account for 2.6% of all cancer deaths in England and Wales and the incidence is increasing by approximately 5% per year, although reasons for this increase are unknown. The Experiments To gain a better understanding of the biology underlying NHL, polysomal mRNA profiling was performed on 6 cell lines (Ros 50, Val, DoHH-2, SuDHL-6, OCI-LY19 and DB) derived from patients with either follicular lymphoma or DLCBL (diffuse large cell B cell lymphoma ) that have the t(14:18)(q32:q11) translocation and as a consequence many have increased expression of BCL2 (figure 1). Two controls ...

A Project of the New Mexico AIDS Education and Training Center. Partially funded by the National Library of Medicine Fact Sheets can be downloaded from the Internet at http://www.aidsinfonet.org AIDS InfoNet www.aidsinfonet.org Fact Sheet Number 512 LYMPHOMA WHAT IS LYMPHOMA ? Lymphoma is a cancer of white blood cells called B-lymphocytes, or B-cells. They multiply rapidly and form tumors. Lymphoma of the brain or spinal cord is called central nervous system (CNS) lymphoma . AIDS-related lymphoma is sometimes called Non-Hodgkin’s Lymphoma (NHL). In 1985, the Centers for Disease Control added NHL to the list of diseases that define AIDS. Hodgkin’s Disease, another type of lymphoma , is rare in people with HIV. The longer you live with a suppressed immune system, the higher the risk of NHL. It can occur ...

International Lymphoma Patient Charter Ratified by Lymphoma Coalition members march 2006 Vision Statement This international charter was created to ensure that the more than one million people living with lymphoma worldwide 1 have access to the best available care, information and support. The number of lymphoma cases is increasing rapidly 2 and there is a critical need for patients to be better informed regarding their disease. 3 Much can be done to improve the current situation and this is the responsibility of society as a whole, including healthcare professionals, patient groups/advocates, governments, insurers, payors/funders, clinicians, researchers and industry. To ensure that lymphoma patients receive the best treatment available, it is vital that the rights outlined in this charter are adopted globally. All patients ...

The Leukemia & Lymphoma Society Silicon Valley & Monterey Bay Chapter Schedule of Events for Patients and their family and friends Summer/Fall 2006 Please note: this list only includes events scheduled by July 2006. Additional events will be scheduled. Please contact Patient Services staff for updated information or check www.lls.org. August 15 th Quarterly Informal Gathering of Chronic Lymphocytic Leukemia (CLL) patients and their family and friends, 6-8pm at Women’s Cancer Resource Center, Oakland. 16 th Understanding Your Treatment Options for Non-Hodgkin Lymphoma . Free Telephone Education Workshop, 9am-11am, Pacific Time. Register online at http://www.rmei.com/nhlreg or go to www.lls.org . 17 th Meet the Expert on Non-Hodgkin Lymphoma Lymphoma : New Insights & Treatments, 6-8pm at Sequoia ...

TYPE OF CANCER: Advanced Solid Tumors & Non-Hodgkin’s lymphoma . TYPE OF TRIAL: Phase I TRIAL SPONSOR: Novartis PRINCIPAL INVESTIGATOR: Sunil Sharma M.D. CONTACT PERSON: Linda Robinson (702) 822-5370 STUDY SUMMARY A Phase IA, two-arm, multi-center, dose escalating study of LBH589 administered intravenously on two dose schedules in adult patients with advanced solid tumors & non-Hodgkin’s lymphoma . TREATMENT OVERVIEW • Each treatment cycle is 21 or 28 days each depending on which study arm. • The duration of this study is variable. • Patient needs to be seen by the physician on Days 1, 3, 8, 10, 15 for each cycle. PRE-TREATMENT ASSESSMENTS • Chest X-Ray • CT scan of the Abdomen/Pelvis/Chest • Bone Scan (if necessary) Page 2 ENTRANCE CRITERIA FOR PARTICIPATION IN TRIAL INCLUSION CRITERIA ...

Patient Information File: CF281 Page 1 of 7 Consent for: Procedures for lymphoma treatment (child) Cambridge University Hospitals NHS Foundation Trust Parent agreement to investigation or treatment For parents of a child who has lymphoma – Routine procedures under general anaesthetic for the whole course of lymphoma treatment • • • Lumbar puncture (to obtain samples of cerebrospinal fluid - CSF) Intrathecal chemotherapy (part of leukaemia treatment) Bone marrow aspirate and trephine (to sample the bone marrow using a smaller or larger needle) Authors: Paediatric Oncology Unit • These procedures are usually carried out as day-case procedures in the Paediatric Day Unit at Addenbrooke’s Hospital • Please ask about anything you do not fully understand or wish to have explained in more detail. • If you would like ...

THE LEUKEMIA & LYMPHOMA SOCIETY HONORS SUSAN WHITING WITH HUMANITARIAN AWARD Society Praises Her “Commitment and Compassion” to Inspire Others The Fairfield County Chapter of The Leukemia & Lymphoma Society honored Susan D. Whiting as the recipient of the 2006 Humanitarian Award. Ms. Whiting accepted the award from Society member Zeena Hine at the Chapter’s 7th Annual Dinner and Auction on April 27, 2006. The Leukemia & Lymphoma Society is a national voluntary association dedicated to finding the cause and eventually the cure for leukemia, lymphoma , Hodgkin’s disease and myeloma and to improve the quality of life of patients and their families. All proceeds from the event have been directed to the mission of the society. Ms. Whiting’s remarks are below. # # # Thank you Zeena, and good evening everyone. I’m honored to be here among so many distinguished and courageous ...

BioGenex offers a vast spectrum of high quality antibodies for both diagnostic and reference laboratories, with an emphasis on cancer and infectious diseases. BioGenex strives to support your efforts in clinical diagnostics and drug discovery development as we continue to expand our antibody product line offering. The following antibodies have been optimized for immunohistochemistry procedures on formalin-fixed, paraffin-embedded tissue sections. B Cell Associated B Cell Associated Lymphoma Panel Lymphoma Panel Clone Localization Catalog No. B4 Mem 264-M,C The CD19 antigen is a critical signal transduction molecule that regu- lates B lymphocyte development, activation, and differentiation. This antibody has been used for studies in B cell targeted therapy of leu- kemia and lymphoma as the antibody is very specific for B-cells. CD19 ...

LYMPHOMA PCP. ELIGIBILITY CRITERIA INCLUSION CRITERIA: To be eligible for inclusion in this trial, all of the below boxes should be ticked. • Biopsy proven diagnosis of low grade non-Hodgkin’s lymphoma including the following histological subtypes: Follicular lymphoma , Follicular mixed small-cleaved and large cell, Diffuse small lymphocytic lymphoma , Lymphoplasmacytic lymphoma , Splenic marginal zone lymphoma , Extranodal marginal zone lymphoma of MALT type, Nodal marginal zone B-cell lymphoma Low grade B cell lymphoma not otherwise specified. • Previously untreated disease. • Able to undergo study procedures / treatment. • ECOG performance status grade < 2. • > 18 years of age. • Available for follow-up for a minimum of 12 months. • Able to provide informed consent. EXCLUSION CRITERIA: To be eligible for ...

ELIGIBILITY FORM Rituximab (Rituxan) for Aggressive Histology Lymphoma (This form should be completed before the first dose is dispensed) 1. PATIENT SURNAME 2. GIVEN NAME _ 3. DATE OF BIRTH __ __ • __ __ • __ __ Day Month Year 4. HEALTH INSURANCE NUMBER __ 5. CENTRE (Circle correct response) 1 Hamilton 2 Kingston 3 London 4 Ottawa Civic 5 Ottawa General 6 Sudbury 7 Thunder Bay 8 Toronto-Sunnybrook 9 Windsor 10 PMH 11 Other (specify below) Other : __ 6. ATTENDING PHYSICIAN __ If not a Cancer Centre physician, please indicate your phone number __ 7. ELIGIBILITY a. Patient has aggressive histology lymphoma - Yes - Diffuse Large B-Cell Lymphoma (DLBCL) or a variant of DLBCL (e.g. mediastinal sclerosing ...

ELIGIBILITY FORM for Rituximab (Rituxan) for Lymphoma (This form should be completed before the first dose is dispensed) 1. PATIENT SURNAME 2. GIVEN NAME _ 3. DATE OF BIRTH __ __ • __ __ • __ __ 4. HEALTH INSURANCE NUMBER Day Month Year 5. CENTRE (Circle correct response) 1 Hamilton 2 Kingston 3 London 4 Ottawa Civic 5 Ottawa General 6 Sudbury 7 Thunder Bay 8 Toronto-Sunnybrook 9 Windsor 10 PMH 11 Other (specify below) Other : __ 6. ATTENDING PHYSICIAN __ If not a Cancer Centre physician, please indicate your phone number __ 7. ELIGIBILITY a. Patient has i. follicular lymphoma and is unable to tolerate further chemotherapy Yes due to haematologic toxicity ii. follicular lymphoma and has failed anthracycline or purine analog ...

ELIGIBILITY FORM Rituximab (Rituxan) in Combination with Chemotherapy for Lymphoma (This form should be completed before the first dose is dispensed) 1. PATIENT SURNAME 2. GIVEN NAME _ 3. DATE OF BIRTH __ __ • __ __ • __ __ 4. HEALTH INSURANCE NUMBER Day Month Year 5. CENTRE (Circle correct response) 1 Hamilton 2 Kingston 3 London 4 Ottawa Civic 5 Ottawa General 6 Sudbury 7 Thunder Bay 8 Toronto-Sunnybrook 9 Windsor 10 PMH 11 Other (specify below) Other : __ 6. ATTENDING PHYSICIAN __ If not a Cancer Centre physician, please indicate your phone number __ 7. ELIGIBILITY a. Patient has follicular lymphoma or other indolent B-cell histology lymphoma Yes e.g. mantle cell lymphoma , marginal zone lymphoma and lymphoplasmacytoid ...